# EMTRICITABINE; RILPIVIRINE; TENOFOVIR ALAFENAMIDE
> **ANDA214058** · Abbreviated New Drug Application (Generic) · Sponsor: CIPLA LIMITED · Approved 2022-09-27
## Drug
- **FDA Application Number:** ANDA214058
- **Application type:** Abbreviated New Drug Application (Generic)
- **Brand name:** EMTRICITABINE; RILPIVIRINE; TENOFOVIR ALAFENAMIDE
- **Generic name:** Emtricitabine
- **Active ingredients:** EMTRICITABINE; RILPIVIRINE; TENOFOVIR ALAFENAMIDE
- **Dosage form:** TABLET
- **Route:** ORAL
- **Marketing status:** None (Tentative Approval)
- **Sponsor:** CIPLA LIMITED
- **First approval:** 2022-09-27
## Source
- [Drugs@FDA application overview](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214058)
---
*MORVS · CC0 1.0*